AUGUST 1 RESEARCH REVIEW
Many of you have asked me to “see the research”. I hear you and I’m so excited that you’re ready to take a deeper look at the science behind regenerative medicine.
I’m launching a new series called, “Research Review” where together we take a deep dive into the research driving innovations within regenerative medicine.
We’ll start with one of my favorite articles:
Wharton’s Jelly-Derived Mesenchymal Stem Cells: Phenotypic Characterization and Optimizing Their Therapeutic Potential for Clinical Applications
Int. J. Mol. Sci. 2013, 14, 11692-11712; doi:10.3390/ijms140611692
Dae-Won Kim 1,2, Meaghan Staples 2, Kazutaka Shinozuka 2, Paolina Pantcheva 2, Sung-Don Kang 1 and Cesar V. Borlongan 2,*
The complete article is located at this link if you’d like to spend some time studying this topic. https://iamregen.com/wp-content/uploads/2019/07/WJ-MSCs-1.pdf
In the world of regenerative medicine, many doctors and scholars devote an exorbitant amount of time to one pinnacle point of debate. Which cells are better– cells from donated umbilical cords (allogenic) or using your own cells (autologous)?
The article we’re diving into here states the authors’ findings clearly: “MSCs harvested from the “young” WJ are considered much more proliferative, immunosuppressive, and even therapeutically active stem cells than those isolated from older, adult tissue sources such as the bone marrow or adipose”.
After a lengthy explanation of the stem cells mechanism of actions, the authors explore possible clinical uses (with research citations):
- cancer therapy (to be clear, we do not treat cancer),
- cardiovascular disease,
- cartilage regeneration,
- peripheral nerve repair,
- and cardiac differentiation (to augment pig valve transplants).
As you can see, there’s so much to explore and understand when it comes to regenerative medicine. Together, we’ll tackle the core topics you need to grasp in order to make the best health decisions for you and your loved ones.
I hope you enjoy this article as much as I did!